SchrodingerSDGR
SDGR
About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Employees: 787
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $5M
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
9% more capital invested
Capital invested by funds: $1.19B [Q4 2024] → $1.3B (+$112M) [Q1 2025]
6.28% more ownership
Funds ownership: 97.19% [Q4 2024] → 103.47% (+6.28%) [Q1 2025]
2% more funds holding
Funds holding: 210 [Q4 2024] → 215 (+5) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
46%
upside
Avg. target
$30
46%
upside
High target
$30
46%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Aleksey Yefremov | 46%upside $30 | Overweight Maintained | 14 Jul 2025 |
Financial journalist opinion
Based on 6 articles about SDGR published over the past 30 days
Neutral
Business Wire
5 days ago
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which.
Positive
Zacks Investment Research
1 week ago
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration
The Material Informatics Companies Quadrant presents an in-depth analysis of the global material informatics market. This industry review highlights leading companies, technological advancements, and trends, evaluating over 140 companies to identify the top 17 leaders. Material informatics leverages software to advance materials science, aiding industries like automotive, aerospace, and electronics. Companies like Schrödinger, Dassault Systèmes, and Citrine Informatics are key players, employing partnerships and innovations to enhance their market position. This quadrant assesses companies on revenue, growth strategies, and product footprint, underscoring the dynamic nature of the material informatics sector. The Material Informatics Companies Quadrant presents an in-depth analysis of the global material informatics market. This industry review highlights leading companies, technological advancements, and trends, evaluating over 140 companies to identify the top 17 leaders. Material informatics leverages software to advance materials science, aiding industries like automotive, aerospace, and electronics. Companies like Schrödinger, Dassault Systèmes, and Citrine Informatics are key players, employing partnerships and innovations to enhance their market position. This quadrant assesses companies on revenue, growth strategies, and product footprint, underscoring the dynamic nature of the material informatics sector.
Neutral
Business Wire
1 week ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 14, 2025, the company granted restricted stock units (RSUs) with respect to 3,488 shares of the company's common stock to three newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.
Neutral
Business Wire
1 week ago
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with a goal of leveraging Schrödinger's advanced computational platform and Ajax's structural biology insights to develop a pipeline of novel molecules, with a focus on JAK inhibitors. Ajax's lead candidate from the collaboration, AJ1-11.
Neutral
PRNewsWire
4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Business Wire
1 month ago
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. “We are excited to receive Fast Track designation for SGR-1505, which underscores the significant need in patient.
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (“Schrödinger” or the “Company”) (NASDAQ: SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Charts implemented using Lightweight Charts™